• Je něco špatně v tomto záznamu ?

Mild behavioral impairment in early Alzheimer's disease and its association with APOE and BDNF risk genetic polymorphisms

V. Matuskova, K. Veverova, DJ. Jester, V. Matoska, Z. Ismail, K. Sheardova, H. Horakova, J. Cerman, J. Laczó, R. Andel, J. Hort, M. Vyhnalek

. 2024 ; 16 (1) : 21. [pub] 20240126

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc24007499

Grantová podpora
T32 MH019934 NIMH NIH HHS - United States
T32MH019934 NIMH NIH HHS - United States

BACKGROUND: Mild behavioral impairment (MBI) has been commonly reported in early Alzheimer's disease (AD) but rarely using biomarker-defined samples. It is also unclear whether genetic polymorphisms influence MBI in such individuals. We thus aimed to examine the association between the cognitive status of participants (amnestic mild cognitive impairment (aMCI-AD) vs cognitively normal (CN) older adults) and MBI severity. Within aMCI-AD, we further examined the association between APOE and BDNF risk genetic polymorphisms and MBI severity. METHODS: We included 62 aMCI-AD participants and 50 CN older adults from the Czech Brain Aging Study. The participants underwent neurological, comprehensive neuropsychological examination, APOE and BDNF genotyping, and magnetic resonance imaging. MBI was diagnosed with the Mild Behavioral Impairment Checklist (MBI-C), and the diagnosis was based on the MBI-C total score ≥ 7. Additionally, self-report instruments for anxiety (the Beck Anxiety Inventory) and depressive symptoms (the Geriatric Depression Scale-15) were administered. The participants were stratified based on the presence of at least one risk allele in genes for APOE (i.e., e4 carriers and non-carriers) and BDNF (i.e., Met carriers and non-carriers). We used linear regressions to examine the associations. RESULTS: MBI was present in 48.4% of the aMCI-AD individuals. Compared to the CN, aMCI-AD was associated with more affective, apathy, and impulse dyscontrol but not social inappropriateness or psychotic symptoms. Furthermore, aMCI-AD was related to more depressive but not anxiety symptoms on self-report measures. Within the aMCI-AD, there were no associations between APOE e4 and BDNF Met and MBI-C severity. However, a positive association between Met carriership and self-reported anxiety appeared. CONCLUSIONS: MBI is frequent in aMCI-AD and related to more severe affective, apathy, and impulse dyscontrol symptoms. APOE and BDNF polymorphisms were not associated with MBI severity separately; however, their combined effect warrants further investigation.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24007499
003      
CZ-PrNML
005      
20240423160018.0
007      
ta
008      
240412s2024 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1186/s13195-024-01386-y $2 doi
035    __
$a (PubMed)38279143
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Matuskova, Veronika $u Department of Neurology, Memory Clinic, Charles University, Second Faculty of Medicine and Motol University Hospital, V Uvalu 84, 150 06, Prague, Czech Republic $u International Clinical Research Center, St. Anne's University Hospital, Brno, Czech Republic
245    10
$a Mild behavioral impairment in early Alzheimer's disease and its association with APOE and BDNF risk genetic polymorphisms / $c V. Matuskova, K. Veverova, DJ. Jester, V. Matoska, Z. Ismail, K. Sheardova, H. Horakova, J. Cerman, J. Laczó, R. Andel, J. Hort, M. Vyhnalek
520    9_
$a BACKGROUND: Mild behavioral impairment (MBI) has been commonly reported in early Alzheimer's disease (AD) but rarely using biomarker-defined samples. It is also unclear whether genetic polymorphisms influence MBI in such individuals. We thus aimed to examine the association between the cognitive status of participants (amnestic mild cognitive impairment (aMCI-AD) vs cognitively normal (CN) older adults) and MBI severity. Within aMCI-AD, we further examined the association between APOE and BDNF risk genetic polymorphisms and MBI severity. METHODS: We included 62 aMCI-AD participants and 50 CN older adults from the Czech Brain Aging Study. The participants underwent neurological, comprehensive neuropsychological examination, APOE and BDNF genotyping, and magnetic resonance imaging. MBI was diagnosed with the Mild Behavioral Impairment Checklist (MBI-C), and the diagnosis was based on the MBI-C total score ≥ 7. Additionally, self-report instruments for anxiety (the Beck Anxiety Inventory) and depressive symptoms (the Geriatric Depression Scale-15) were administered. The participants were stratified based on the presence of at least one risk allele in genes for APOE (i.e., e4 carriers and non-carriers) and BDNF (i.e., Met carriers and non-carriers). We used linear regressions to examine the associations. RESULTS: MBI was present in 48.4% of the aMCI-AD individuals. Compared to the CN, aMCI-AD was associated with more affective, apathy, and impulse dyscontrol but not social inappropriateness or psychotic symptoms. Furthermore, aMCI-AD was related to more depressive but not anxiety symptoms on self-report measures. Within the aMCI-AD, there were no associations between APOE e4 and BDNF Met and MBI-C severity. However, a positive association between Met carriership and self-reported anxiety appeared. CONCLUSIONS: MBI is frequent in aMCI-AD and related to more severe affective, apathy, and impulse dyscontrol symptoms. APOE and BDNF polymorphisms were not associated with MBI severity separately; however, their combined effect warrants further investigation.
650    _2
$a lidé $7 D006801
650    _2
$a senioři $7 D000368
650    _2
$a mozkový neurotrofický faktor $x genetika $7 D019208
650    12
$a Alzheimerova nemoc $x diagnostické zobrazování $x epidemiologie $x genetika $7 D000544
650    _2
$a genotyp $7 D005838
650    12
$a kognitivní dysfunkce $x diagnostické zobrazování $x epidemiologie $x genetika $7 D060825
650    _2
$a polymorfismus genetický $x genetika $7 D011110
650    _2
$a neuropsychologické testy $7 D009483
650    _2
$a apolipoproteiny E $x genetika $7 D001057
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Veverova, Katerina $u Department of Neurology, Memory Clinic, Charles University, Second Faculty of Medicine and Motol University Hospital, V Uvalu 84, 150 06, Prague, Czech Republic
700    1_
$a Jester, Dylan J $u Women's Operational Military Exposure Network (WOMEN), VA Palo Alto Health Care System, Palo Alto, CA, USA
700    1_
$a Matoska, Vaclav $u Department of Clinical Biochemistry, Hematology and Immunology, Homolka Hospital, Prague, Czech Republic
700    1_
$a Ismail, Zahinoor $u Departments of Psychiatry and Clinical Neurosciences, Cumming School of Medicine, Hotchkiss Brain Institute, University of Calgary, Calgary, AB, Canada $u Clinical and Biomedical Sciences, Faculty of Health and Life Sciences, University of Exeter, Exeter, United Kingdom
700    1_
$a Sheardova, Katerina $u International Clinical Research Center, St. Anne's University Hospital, Brno, Czech Republic
700    1_
$a Horakova, Hana $u Department of Neurology, Memory Clinic, Charles University, Second Faculty of Medicine and Motol University Hospital, V Uvalu 84, 150 06, Prague, Czech Republic $u International Clinical Research Center, St. Anne's University Hospital, Brno, Czech Republic $u Department of Clinical Psychology, Motol University Hospital, Prague, Czech Republic
700    1_
$a Cerman, Jiri $u Department of Neurology, Memory Clinic, Charles University, Second Faculty of Medicine and Motol University Hospital, V Uvalu 84, 150 06, Prague, Czech Republic $u International Clinical Research Center, St. Anne's University Hospital, Brno, Czech Republic
700    1_
$a Laczó, Jan $u Department of Neurology, Memory Clinic, Charles University, Second Faculty of Medicine and Motol University Hospital, V Uvalu 84, 150 06, Prague, Czech Republic
700    1_
$a Andel, Ross $u Department of Neurology, Memory Clinic, Charles University, Second Faculty of Medicine and Motol University Hospital, V Uvalu 84, 150 06, Prague, Czech Republic $u International Clinical Research Center, St. Anne's University Hospital, Brno, Czech Republic $u Center for Innovation in Healthy and Resilient Aging, Edson College of Nursing and Health Innovation, Arizona State University, Phoenix, AZ, USA
700    1_
$a Hort, Jakub $u Department of Neurology, Memory Clinic, Charles University, Second Faculty of Medicine and Motol University Hospital, V Uvalu 84, 150 06, Prague, Czech Republic $u International Clinical Research Center, St. Anne's University Hospital, Brno, Czech Republic
700    1_
$a Vyhnalek, Martin $u Department of Neurology, Memory Clinic, Charles University, Second Faculty of Medicine and Motol University Hospital, V Uvalu 84, 150 06, Prague, Czech Republic. martin.vyhnalek@lfmotol.cuni.cz
773    0_
$w MED00172451 $t Alzheimer's research & therapy $x 1758-9193 $g Roč. 16, č. 1 (2024), s. 21
856    41
$u https://pubmed.ncbi.nlm.nih.gov/38279143 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20240412 $b ABA008
991    __
$a 20240423160014 $b ABA008
999    __
$a ok $b bmc $g 2081476 $s 1217266
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2024 $b 16 $c 1 $d 21 $e 20240126 $i 1758-9193 $m Alzheimer's research & therapy $n Alzheimers Res Ther $x MED00172451
GRA    __
$a T32 MH019934 $p NIMH NIH HHS $2 United States
GRA    __
$a T32MH019934 $p NIMH NIH HHS $2 United States
LZP    __
$a Pubmed-20240412

Najít záznam

Citační ukazatele

Možnosti archivace